FFF Enterprises Inc., a reputable specialty drug distributor and healthcare company, has partnered with Verrica Pharmaceuticals Inc. to distribute YCANTH™ (cantharidin) Topical Solution 0.7%, the first FDA-approved treatment for molluscum contagiosum in both adult and pediatric patients aged 2 and older. Molluscum contagiosum is a viral skin infection that commonly affects children, spread through skin-to-skin contact. This partnership addresses an unmet medical need and ensures wider access to this safe and effective treatment. Distribution of YCANTH is set to commence in September.
FFF Enterprises Inc., recognized as the nation’s most trusted specialty drug distributor and diversified healthcare company, has partnered with Verrica Pharmaceuticals Inc. to distribute YCANTH™ (cantharidin) Topical Solution 0.7%, the first FDA approved treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.
The U.S. Food and Drug Administration (FDA) describes molluscum contagiosum as “a viral skin infection that can cause white, pink, or flesh-colored bumps that may itch or become irritated. These bumps can happen alone or in groups almost anywhere on the skin, including the face, neck, arms, legs, stomach, and genital area. Molluscum is transmitted by skin-to-skin contact and can affect anyone at any age, though it’s most common among children under 10.” Molluscum contagiosum is classified as a poxvirus and is typically spread in settings where children interact, such as households, schools, and swimming pools. The FDA found that YCANTH is a safe and effective topical treatment for patients as young as two years old.
“Before the FDA approval of YCANTH, there was a significant unmet need for patients—often children—and their healthcare providers. FFF is honored to be part of this pioneering event in medical dermatology, and we will ensure that physicians can access YCANTH through standard distribution or consignment. Verrica’s commitment to the research, development, and approval of this important treatment aligns with FFF’s industry leadership, expertise, and our mission of Helping Healthcare Care®,” said Patrick M. Schmidt, chief executive officer of FFF Enterprises. “We look forward to distributing YCANTH beginning in September.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: BioSpace